title: Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
abstract: The cynomolgus monkeys received a unilateral intracarotid injection of the neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in order to induce a chronic model of hemi-parkinsonism. The procedure was well tolerated by the animals. Unilateral injection of MPTP caused rigidity and bradykinesia of the contralateral limbs, but the animals were able to eat and drink without levodopa therapy. During spontaneous motor activity, animals rotated toward the lesioned side whereas systemic apomorphine injection stimulated circling toward the normal non-lesioned side. Twelve weeks after MPTP injection, we found a marked reduction in striatal and nigral [3H]-mazindol binding on the MPTP-injected side which is indicative of a loss in both dopaminergic nerve terminals and cell bodies. The unilateral dopaminergic denervation was associated with an ipsilateral increase in striatal and a reduction in nigral [3H]-spiperone-labelled D2 dopamine receptors; these changes are consistent with the known localization of the D2 receptors on striatal dopaminergic nerve terminals and on nigral dopaminergic cell bodies. In contrast, no changes in [3H]-SCH 23390-labelled D1 dopamine receptors were observed at the level of either the striatum or the substantia nigra. This study describes a well tolerated procedure which induces a clinical and morphological hemi-parkinsonian syndrome. This animal model may be useful in the studies of new antiparkinsonian drugs, for testing the functional efficacy of brain tissue implants and in the understanding of the physiopathogenesis of levodopa-induced dyskinesias.
authors.affiliation: Départment of Neurology, College of Physicians & Surgeons, Columbia University, New York, N.Y. 10032.
authors.forename: S
authors.initials: S
authors.lastname: Przedborski
authors.forename: V
authors.initials: V
authors.lastname: Jackson-Lewis
authors.forename: S
authors.initials: S
authors.lastname: Popilskis
authors.forename: V
authors.initials: V
authors.lastname: Kostic
authors.forename: M
authors.initials: M
authors.lastname: Levivier
authors.forename: S
authors.initials: S
authors.lastname: Fahn
authors.forename: J L
authors.initials: JL
authors.lastname: Cadet
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage*; D000818:Animals; D001345:Autoradiography; D001923:Brain Chemistry; D002339:Carotid Arteries; D003342:Corpus Striatum / Q000737:chemistry; D004195:Disease Models, Animal; D005260:Female; D008253:Macaca mulatta; D008297:Male; D008454:Mazindol / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000378:metabolism; D011954:Receptors, Dopamine / Q000032:analysis*; D013378:Substantia Nigra / Q000737:chemistry
chemical_list: D011954:Receptors, Dopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008454:Mazindol